Mode
Text Size
Log in / Sign up

Preterm delivery

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Preterm delivery

5 trials tracked for Preterm delivery: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 11 citations.

5Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 2 Other / NA 2
  1. Phase 3 Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM) Completed · 11 cited
  2. Phase 4 A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome Completed
  3. Phase 3 PREGNANT Short Cervix Trial Completed
  4. N/A Neonatal Outcome by Reason for Delivery Completed
  5. N/A Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Preterm delivery: what the trials found

Administration of a second course of ACS with either Betamethasone or Dexamethasone significantly reduced the composite neonatal morbidity in infants born at less than 34 weeks gestation (p=0.002) 1. This intervention also resulted in lower rates of babies requiring ventilatory support within the first 28 days of life compared to the control group 1.

Progesterone administration has been shown to significantly reduce the number of participants with births at less than or equal to 32 6/7 weeks gestation (p=0.020) 3. Furthermore, progesterone use was associated with a significant reduction in neonatal morbidities including Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Intraventricular Hemorrhage (IVH), proven sepsis, and Necrotizing Enterocolitis (NEC) (p=0.048) 3.

Progesterone treatment also demonstrated a statistically significant reduction in the number of subjects with preterm births across multiple gestational thresholds, specifically at ≤27 6/7, ≤34 6/7, and <36 6/7 weeks gestation (p=0.036) 3.

For the clinician treating this condition

  • A second course of ACS with Betamethasone or Dexamethasone is associated with reduced composite neonatal morbidity and lower requirements for ventilatory support in infants born <34 weeks gestation 1.
  • Progesterone administration significantly reduces the incidence of preterm births at various gestational thresholds and decreases the occurrence of major neonatal morbidities such as RDS, BPD, IVH, sepsis, and NEC 3.

AI synthesis of 2 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.